

SIXTH ELEMENT CAPITAL WELCOMES BOSTON PHARMACEUTICAL'S PORTFOLIO UPDATE

LONDON, UK, 5 January 2018. Sixth Element Capital (6EC), the specialist cancer investment firm, welcomes today's update on Boston Pharmaceutical's portfolio. On their portfolio page (www.bostonpharmaceuticals.com/portfolio) Boston Pharmaceuticals has made the following update:

"BOS172722 is an inhibitor of monopolar spindle 1 (MPS1) checkpoint with potential for the treatment of various forms of breast cancer. Boston Pharmaceuticals is currently enrolling patients in an ongoing Phase 1 trial for the potential treatment of triple negative breast cancer. BOS172722 was acquired from CRT Pioneer Fund LP (managed by Sixth Element Capital) and was discovered at the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London. The research was originally supported by Cancer Research UK and Breast Cancer Now."

Notes:

About Sixth Element Capital LLP and the CRT Pioneer Fund

Sixth Element Capital LLP (6EC) is a UK based fund manager, which manages the CRT Pioneer Fund. 6EC's experienced partners focus on creative and collaborative novel financing solutions designed to fund and manage innovative science in order to bring new therapeutic products and technologies to market, creating long term value and benefit to stakeholders. The CRT Pioneer Fund is a specialist oncology investment fund established by 6EC in 2012. The £70 million fund is dedicated to investments in oncology development programmes in Europe. The fund was established to bridge the investment gap between cancer drug discovery and early clinical development. To date the Fund has made twelve investments.

For more information, please see <http://www.sixthelementcapital.com>.